Mutations in DNMT3A and TET2 were detected in the majority of patients with AITL in both pre-treatment tumours (8/12 and 11/12, respectively) and in ctDNA where available (5/6 and 6/6, respectively). This evidence concerns the gene TET2 and angioimmunoblastic T-cell lymphoma.